🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

ARE YOU READY? Immerse yourself in a world of innovation for myelofibrosis. Visit #ThePortal at #ASH24, Booth 2147. #DiscoveriesBeyondTheOrdinary

THIS IS YOUR MOMENT. Let curiosity get the best of you. See future possibilities in myelofibrosis at #ThePortal. #ASH24 Booth 2147. #DiscoveriesBeyondTheOrdinary

IT’S UP TO YOU. Explore bold advances in myelofibrosis. Visit #ThePortal at #ASH24 Booth 2147 to find out more. #MPNSM #DiscoveriesBeyondTheOrdinary

THE TIME IS NOW. At the peak of discovery, possibilities unfold. Visit #ThePortal to see what’s new in myelofibrosis. #ASH24 Booth 2147. #MPNSM #DiscoveriesBeyondTheOrdinary

CONGRESS #ASH24 | PRESENTATION John Mascarenhas, Icahn School of Medicine at Mount Sinai discussed results from the phase III BOREAS study. Navtemadlin treatment improved biomarkers of disease burden in pts with R/R MF, including changes in CD34+ counts, driver mutation burden, and serum inflammatory

#ASH24 Booth 2147. #MPNSM #DiscoveriesBeyondTheOrdinary

Navtemadlin Reduces Markers of Disease Burden in Relapsed/Refractory Myelofibrosis Icahn School of Medicine at Mount Sinai Mount Sinai Health System ASH #ASH24 #hematology onclive.com/view/navtemadl…

The MDM2 inhibitor navtemadlin may target cancer-driving cells and alter its progression in patients with relapsed or refractory myelofibrosis, according to data from a phase 3 trial presented at #ASH24. #MPNs #BloodCancer Read here: curetoday.com/view/navtemadl…

DO NOT BE AFRAID. Beneath the surface lies a future reimagined. Explore novel innovations in myelofibrosis at #ThePortal at #ASH24, Booth 2147. #MPNSM #DiscoveriesBeyondTheOrdinary

#ASH24 Booth 2147. #MPNSM #DiscoveriesBeyondTheOrdinary

Navtemadlin reduced disease biomarkers in relapsed/refractory myelofibrosis, suggesting it targets disease-driving cells and alters progression. Data from the phase 3 BOREAS trial were presented at #ASH24. #mpnsm | Icahn School of Medicine at Mount Sinai ASH targetedonc.com/view/navtemadl…

#ASH24 Compared with best available therapies, treatment with the MDM2 inhibitor #navtemadlin led to greater improvements in SVR35 and TSS50 among patients with #myelofibrosis that was R/R to JAK inhibitors: ow.ly/3KXt50Un7OT

Disease-driving cells in patients with relapsed/refractory myelofibrosis may be targetable with the investigational p53-potentiating, best-in-class MDM2 inhibitor navtemadlin. #ASH24 | ASH cancernetwork.com/view/novel-mdm…

Navtemadlin Reduces Spleen Size and Symptom Score in R/R Myelofibrosis ASH #ASH24 #mpnsm #oncology onclive.com/view/navtemadl…

CONGRESS | #ASH24 | PRESENTATION John Mascarenhas Icahn School of Medicine at Mount Sinai shares findings from the phase III BOREAS study investigating navtemadlin vs BAT in JAK inhibitor R/R MF (N = 183). Navtemadlin monotherapy was safe and effective, demonstrating clinically relevant efficacy

Published by VJHemOnc vjhemonc.com/video/e5cmmvuf…

Published by VJHemOnc vjhemonc.com/video/kad5gc0y…

Kartos is excited to share the US launch of a website to support our global Ph3 study #POIESISTrial of navtemadlin (MDM2i) or placebo as add-on to ruxolitinib in patients with myelofibrosis who have a suboptimal response to ruxolitinib treatment. Future website launches in other